Laza Medical raises up to $160M Series B led by GE HealthCare for AI cath lab

What's the deal? Laza Medical, a Shifamed portfolio company developing AI-powered robotic imaging for cardiac procedures, has raised up to $160 million in Series B structured financing. GE HealthCare led the round, with returning investors Unorthodox VenturesDealroom has a profile for this one. Try Dealroom →, PA MedTech, and AMEDDealroom has a profile for this one. Try Dealroom → participating.

Why it matters: At $160 million, the round sits in the 97th percentile of all Series B rounds for US health startups, based on a sample of 3,704 deals. It is also a steep step-up from Laza's $36 million Series A in 2023, with GE HealthCare moving from early backer to lead investor.

What's the endgame? The Los Gatos, California company wants to transform the cardiac catheterisation lab with imaging that simplifies procedures and eases demand for specialist expertise. The funds will support that work and lay the groundwork for future robotic-enabled interventions.

What they're saying: "The cath lab is poised for a fundamental evolution, and intelligent imaging powered by AI will play a defining role in what comes next," said Amr Salahieh, founder and board chairman at Laza Medical.

What could go wrong? The Laza Medical System remains under development and is not approved for commercial sale in any geography. Clinical validation and adoption — not funding — will decide whether its proposed workflow materialises.

The signal: The round reflects a wider push to merge imaging, AI, and robotics in procedure suites. PhilipsDealroom has a profile for this one. Try Dealroom → recently won an ARPA-H award of up to $33.7 million for AI-enabled robotic stroke care, while Canon Medical and Stereotaxis paired imaging with robotic navigation for electrophysiology labs. What stands out here is the scale of strategic backing from a major imaging incumbent.

Read more: prnewswire.com

Image credit: Laza Medical